QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
NASDAQ:RYTM

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price & News

$17.64
+0.47 (+2.74%)
(As of 02:51 PM ET)
Compare
Today's Range
$16.95
$17.70
50-Day Range
$16.32
$21.15
52-Week Range
$3.13
$34.99
Volume
159,959 shs
Average Volume
637,726 shs
Market Capitalization
$1.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
106.1% Upside
$36.00 Price Target
Short Interest
Bearish
15.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.56mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$15,960 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.27) to ($2.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

1473rd out of 1,980 stocks

Pharmaceutical Preparations Industry

743rd out of 978 stocks


RYTM stock logo

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Georgia St. Rhythm & Blues
See More Headlines

RYTM Price History

RYTM Company Calendar

Last Earnings
5/02/2023
Today
6/02/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+105.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-181,120,000.00
Net Margins
-537.16%
Pretax Margin
-537.16%

Debt

Sales & Book Value

Annual Sales
$23.64 million
Book Value
$3.87 per share

Miscellaneous

Free Float
54,695,000
Market Cap
$998.29 million
Optionable
Optionable
Beta
1.72

Key Executives

  • David P. Meeker
    Chairman, President & Chief Executive Officer
  • Hunter C. Smith
    Chief Financial Officer & Treasurer
  • Brieana Buckley
    Vice President-Medical Affairs
  • Joseph Shulman
    Chief Technical Officer
  • Yann Mazabraud
    Executive Vice President & Head-International













RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price forecast for 2023?

6 Wall Street analysts have issued twelve-month price targets for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $20.00 to $56.00. On average, they expect the company's share price to reach $36.00 in the next year. This suggests a possible upside of 105.0% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2023?

Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM shares have decreased by 39.7% and is now trading at $17.56.
View the best growth stocks for 2023 here
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.21. The business had revenue of $11.50 million for the quarter, compared to analysts' expectations of $12.12 million. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 75.16% and a negative net margin of 537.16%. The firm's revenue was up 666.7% on a year-over-year basis. During the same quarter last year, the company earned ($1.05) earnings per share.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (11.43%), Federated Hermes Inc. (6.85%), BlackRock Inc. (6.65%), State Street Corp (4.59%), FMR LLC (1.23%) and Assenagon Asset Management S.A. (1.17%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $17.56.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $998.29 million and generates $23.64 million in revenue each year. The company earns $-181,120,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

The company employs 140 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -